CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY
Enhanced Shear-Induced Platelet Aggregation in Patients Who Experience Subacute Stent Thrombosis
A Case-Control Study
Nadine Ajzenberg, MD, PhD*,*,
Pierre Aubry, MD ,
Marie-Genevieve Huisse, MD*,
Agnés Cachier, MD,
Walid El Amara, MD,
Laurent J. Feldman, MD, PhD,
Dominique Himbert, MD,
Dominique Baruch, MD, PhD ,
Marie-Claude Guillin, MD, PhD* and
Ph. Gabriel Steg, MD
* Hématologie et Immunologie, Paris, France
Cardiologie, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France
Hôpital de Bicêtre, Le Kremlin Bicêtre, France
Manuscript received September 3, 2004;
revised manuscript received October 11, 2004,
accepted October 18, 2004.
* Reprint requests and correspondence to: Dr. Nadine Ajzenberg, Service d’Hématologie et Immunologie, Hôpital Bichat-Claude Bernard, 46 rue Henri Huchard, 75877 Paris Cedex 18, France. (Email: nadine.ajzenberg{at}bch.ap-hop-paris.fr).
OBJECTIVES: The goal of this study was to identify differences in shear-induced platelet aggregation (SIPA) between patients who did or did not experience subacute stent thrombosis (SAT).
BACKGROUND: Despite dual antiplatelet therapy, SAT after coronary stenting occurs in approximately 1% of patients. There is no accepted platelet function test to identify patients at risk.
METHODS: We analyzed platelet aggregation in 10 patients who had experienced SAT (cases), 22 stented patients without SAT (controls), and 17 healthy volunteers (normals). All patients except normals were treated with both aspirin and clopidogrel.
RESULTS: Shear-induced platelet aggregation was higher in cases than in controls at both shear rates of 200 s–1 (40.9 ± 12.2% vs. 18.2 ± 18%, p = 0.013) and 4,000 s–1 (57.4 ± 16.4% vs. 23.4 ± 21.2%, p = 0.009). Moreover, SIPA in cases was significantly higher than in normals both at 200 s–1 (p = 0.013) and 4,000–1 (p = 0.009).
CONCLUSIONS: Shear-induced platelet aggregation is increased in patients experiencing SAT compared with controls receiving dual antiplatelet therapy and to normals receiving no antiplatelet therapy, which suggests increased intrinsic patient-related platelet reactivity in patients with SAT. The predictive value of SIPA for SAT requires prospective investigation.
|
Abbreviations and Acronyms
| | ADP = adenosine diphosphate | | DSP = disappearance of single platelets | | PCI = percutaneous coronary intervention | | PRP = platelet-rich plasma | | SAT = subacute stent thrombosis | | SIPA = shear-induced platelet aggregation | | vWF = von Willebrand factor |
|
Related Article
-
Resistance to Antiplatelet Resistance: Is it Justified?
- Steven R. Steinhubl, Richard Charnigo, and David J. Moliterno
J. Am. Coll. Cardiol. 2005 45: 1757-1758.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
M. P. Bonaca, P. G. Steg, L. J. Feldman, J. F. Canales, J. J. Ferguson, L. Wallentin, R. M. Califf, R. A. Harrington, and R. P. Giugliano
Antithrombotics in acute coronary syndromes.
J. Am. Coll. Cardiol.,
September 8, 2009;
54(11):
969 - 984.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Verstuyft, T. Simon, and R. B. Kim
Personalized medicine and antiplatelet therapy: ready for prime time?
Eur. Heart J.,
August 2, 2009;
30(16):
1943 - 1963.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. H. Riedel, M. Tietke, K. Alfke, R. Stingele, and O. Jansen
Subacute Stent Thrombosis in Intracranial Stenting
Stroke,
April 1, 2009;
40(4):
1310 - 1314.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. H. Jeong, S.-W. Lee, B.-R. Choi, I.-S. Kim, M.-K. Seo, C. H. Kwak, J.-Y. Hwang, and S.-W. Park
Randomized Comparison of Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With High Post-Treatment Platelet Reactivity Results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) Randomized Study.
J. Am. Coll. Cardiol.,
March 31, 2009;
53(13):
1101 - 1109.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. T. Newsome, M. A. Kutcher, and R. L. Royster
Coronary Artery Stents: Part I. Evolution of Percutaneous Coronary Intervention
Anesth. Analg.,
August 1, 2008;
107(2):
552 - 569.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Trenk, W. Hochholzer, M. F. Fromm, L.-E. Chialda, A. Pahl, C. M. Valina, C. Stratz, P. Schmiebusch, H.-P. Bestehorn, H. J. Buttner, et al.
Cytochrome P450 2C19 681G>A Polymorphism and High On-Clopidogrel Platelet Reactivity Associated With Adverse 1-Year Clinical Outcome of Elective Percutaneous Coronary Intervention With Drug-Eluting or Bare-Metal Stents
J. Am. Coll. Cardiol.,
May 20, 2008;
51(20):
1925 - 1934.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-P. Bassand
Unmet needs in antiplatelet therapy
Eur. Heart J. Suppl.,
May 1, 2008;
10(suppl_D):
D3 - D11.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Wallentin
Dual antiplatelet therapy in the drug-eluting stent era
Eur. Heart J. Suppl.,
May 1, 2008;
10(suppl_D):
D38 - D44.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. L. L'Allier, G. Ducrocq, N. Pranno, S. Noble, R. Ibrahim, J. C. Gregoire, F. Azzari, A. Nozza, C. Berry, S. Doucet, et al.
Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: results from the PREPAIR randomized study.
J. Am. Coll. Cardiol.,
March 18, 2008;
51(11):
1066 - 1072.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A. Gurbel, R. C. Becker, K. G. Mann, S. R. Steinhubl, and A. D. Michelson
Platelet Function Monitoring in Patients With Coronary Artery Disease
J. Am. Coll. Cardiol.,
November 6, 2007;
50(19):
1822 - 1834.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Windecker and B. Meier
Late Coronary Stent Thrombosis
Circulation,
October 23, 2007;
116(17):
1952 - 1965.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Campo, M. Valgimigli, D. Gemmati, G. Percoco, L. Catozzi, A. Frangione, F. Federici, F. Ferrari, M. Tebaldi, S. Luccarelli, et al.
Poor Responsiveness to Clopidogrel: Drug-Specific or Class-Effect Mechanism?: Evidence From a Clopidogrel-to-Ticlopidine Crossover Study
J. Am. Coll. Cardiol.,
September 18, 2007;
50(12):
1132 - 1137.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. O. Maree and D. J. Fitzgerald
Variable Platelet Response to Aspirin and Clopidogrel in Atherothrombotic Disease
Circulation,
April 24, 2007;
115(16):
2196 - 2207.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, F. Alfonso, C. Macaya, T. A. Bass, and M. A. Costa
Variability in Individual Responsiveness to Clopidogrel: Clinical Implications, Management, and Future Perspectives
J. Am. Coll. Cardiol.,
April 10, 2007;
49(14):
1505 - 1516.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Angiolillo, S. B. Shoemaker, B. Desai, H. Yuan, R. K. Charlton, E. Bernardo, M. M. Zenni, L. A. Guzman, T. A. Bass, and M. A. Costa
Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients With Diabetes Mellitus and Coronary Artery Disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study
Circulation,
February 13, 2007;
115(6):
708 - 716.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Fitzgerald and A. Maree
Aspirin and Clopidogrel Resistance
Hematology,
January 1, 2007;
2007(1):
114 - 120.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Campo, M. Valgimigli, D. Gemmati, G. Percoco, S. Tognazzo, G. Cicchitelli, L. Catozzi, P. Malagutti, M. Anselmi, C. Vassanelli, et al.
Value of Platelet Reactivity in Predicting Response to Treatment and Clinical Outcome in Patients Undergoing Primary Coronary Intervention: Insights Into the STRATEGY Study
J. Am. Coll. Cardiol.,
December 5, 2006;
48(11):
2178 - 2185.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Hochholzer, D. Trenk, H.-P. Bestehorn, B. Fischer, C. M. Valina, M. Ferenc, M. Gick, A. Caputo, H. J. Buttner, and F.-J. Neumann
Impact of the Degree of Peri-Interventional Platelet Inhibition After Loading With Clopidogrel on Early Clinical Outcome of Elective Coronary Stent Placement
J. Am. Coll. Cardiol.,
November 7, 2006;
48(9):
1742 - 1750.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-P. Collet and G. Montalescot
Premature withdrawal and alternative therapies to dual oral antiplatelet therapy
Eur. Heart J. Suppl.,
October 1, 2006;
8(suppl_G):
G46 - G52.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, C. Ramirez, M. Sabate, P. Jimenez-Quevedo, R. Hernandez, R. Moreno, J. Escaned, F. Alfonso, et al.
Clopidogrel Withdrawal Is Associated With Proinflammatory and Prothrombotic Effects in Patients With Diabetes and Coronary Artery Disease
Diabetes,
March 1, 2006;
55(3):
780 - 784.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. T. Ivandic, P. Schlick, P. Staritz, K. Kurz, H. A. Katus, and E. Giannitsis
Determination of Clopidogrel Resistance by Whole Blood Platelet Aggregometry and Inhibitors of the P2Y12 Receptor
Clin. Chem.,
March 1, 2006;
52(3):
383 - 388.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, O. Ben-Yehuda, D. Berman, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, W. Y.W. Lew, D. Sahn, and S. Tsimikas
Highlights of the Year in JACC 2005
J. Am. Coll. Cardiol.,
January 3, 2006;
47(1):
184 - 202.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Steinhubl, R. Charnigo, and D. J. Moliterno
Resistance to Antiplatelet Resistance: Is it Justified?
J. Am. Coll. Cardiol.,
June 7, 2005;
45(11):
1757 - 1758.
[Full Text]
[PDF]
|
|
|
|
